

# Jatinder Kaur

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/749126/publications.pdf>

Version: 2024-02-01

39  
papers

11,508  
citations

430874

18  
h-index

302126

39  
g-index

42  
all docs

42  
docs citations

42  
times ranked

28714  
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical Review of Bioadsorption on Modified Cellulose and Removal of Divalent Heavy Metals (Cd, Pb,) Tj ETQq1 1	0.784314	54
2	Optimization of a Pyrimidinone Series for Selective Inhibition of Ca <sup>2+</sup> /Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain. Journal of Medicinal Chemistry, 2022, 65, 4667-4686.	6.4	3
3	Novel therapeutic heterocycles as selective cyclooxygenase-2 inhibitors and anti-cancer agents: Synthesis, in vitro bioassay screenings, and molecular docking studies. Journal of Molecular Structure, 2022, 1263, 133141.	3.6	5
4	Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2. Molecules, 2022, 27, 3722.	3.8	1
5	In Cellulo Generation of Fluorescent Probes for Live-Cell Imaging of Cyclooxygenase-2. Chemistry - A European Journal, 2021, 27, 3326-3337.	3.3	4
6	Synthesis and Biological Evaluation of 1,3,5-Trisubstituted 2-Pyrazolines as Novel Cyclooxygenase-2 Inhibitors with Antiproliferative Activity. Chemistry and Biodiversity, 2021, 18, e2000832.	2.1	4
7	Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against <i>Neisseria gonorrhoeae</i> . ACS Infectious Diseases, 2021, 7, 1969-1984.	3.8	48
8	Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells. ACS Medicinal Chemistry Letters, 2021, 12, 798-804.	2.8	5
9	Cu(II) complexes of hydrazones-NSAID conjugates: synthesis, characterization and anticancer activity. Journal of Coordination Chemistry, 2020, 73, 3186-3202.	2.2	4
10	Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant <i>Enterococcus</i> . Journal of Medicinal Chemistry, 2020, 63, 9540-9562.	6.4	57
11	Optimization of a 1,3,4-oxadiazole series for inhibition of Ca <sup>2+</sup> /calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain. European Journal of Medicinal Chemistry, 2019, 162, 568-585.	5.5	22
12	Glutathione S-Transferase-Activatable Ox <sup>2+</sup> -(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo. Journal of Medicinal Chemistry, 2018, 61, 1833-1844.	6.4	17
13	Fluorescent Hexose Conjugates Establish Stringent Stereochemical Requirement by GLUT5 for Recognition and Transport of Monosaccharides. ACS Chemical Biology, 2017, 12, 1087-1094.	3.4	16
14	In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nature Communications, 2017, 8, 1.	12.8	10,736
15	Ruthenium(II) complexes of aroylhydrazones: structural, electrochemical and electrostatic interactions with DNA. Journal of Coordination Chemistry, 2017, 70, 1667-1682.	2.2	2
16	Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation. Organic and Biomolecular Chemistry, 2016, 14, 7250-7257.	2.8	11
17	Design, Synthesis, and Evaluation of an <sup>18</sup> F-Labeled Radiotracer Based on Celecoxib-NBD for Positron Emission Tomography (PET) Imaging of Cyclooxygenase-2 (COX-2). ChemMedChem, 2015, 10, 1635-1640.	3.2	27
18	Synthesis, bioassay studies, and molecular docking of novel 5-substituted 1H tetrazoles as cyclooxygenase-2 (COX-2) inhibitors. Medicinal Chemistry Research, 2015, 24, 78-85.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Fluorophore-Labelled Cyclooxygenase-2 Inhibitors for the Imaging of Cyclooxygenase-2 Overexpression in Cancer: Synthesis and Biological Studies. <i>ChemMedChem</i> , 2014, 9, 109-116.	3.2	36
20	Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 533-536.	1.5	3
21	Hybrid fluorescent conjugates of COX-2 inhibitors: Search for a COX-2 isozyme imaging cancer biomarker. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 163-168.	2.2	37
22	Synthesis of three <sup>18</sup> F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 8052.	2.8	28
23	A diazen-1-ium-1,2-diolate analog of 7-azabenzobicyclo[2.2.1]heptane: Synthesis, nitric oxide and nitroxyl release, in vitro hemodynamic, and anti-hypertensive studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2769-2774.	2.2	2
24	Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?. <i>Future Medicinal Chemistry</i> , 2013, 5, 381-383.	2.3	4
25	1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4288-4295.	3.0	14
26	Synthesis and Biological Investigations of Nitric Oxide Releasing Nateglinide and Meglitinide Type II Antidiabetic Prodrugs: In-Vivo Antihyperglycemic Activities and Blood Pressure Lowering Studies. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7883-7891.	6.4	33
27	<sup>2</sup> -Sulfonylethyl Protected Isopropylamine Diazen-1-ium-1,2-diolates as Nitroxyl (HNO) Donors: Synthesis, <sup>12</sup> -Elimination Fragmentation, HNO Release, Positive Inotropic Properties, and Blood Pressure Lowering Studies. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10262-10271.	6.4	19
28	Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Anti-hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model. <i>ChemMedChem</i> , 2012, 7, 1365-1368.	3.2	17
29	N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2154-2159.	2.2	41
30	Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO <sub>2</sub> NHOH) Cyclooxygenase-2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Anti-inflammatory Agents. <i>ChemMedChem</i> , 2012, 7, 62-67.	3.2	24
31	Aspirin Analogues as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors: Synthesis, Nitric Oxide Release, Molecular Modeling, and Biological Evaluation as Anti-inflammatory Agents. <i>ChemMedChem</i> , 2012, 7, 144-150.	3.2	20
32	ATP selective acridone based fluorescent probes for monitoring of metabolic events. <i>Chemical Communications</i> , 2011, 47, 4472.	4.1	38
33	Isomeric acetoxo analogs of celecoxib and their evaluation as cyclooxygenase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6074-6080.	2.2	11
34	Acridine derivatives: a patent review (2009 - 2010). <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 437-454.	5.0	24
35	Acridone based Cu <sup>2+</sup> -responsive ON/OFF key pad. <i>Sensors and Actuators B: Chemical</i> , 2010, 150, 50-56.	7.8	26
36	Targeting efflux pumps: In vitro investigations with acridone derivatives and identification of a lead molecule for MDR modulation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4212-4223.	3.0	15

#	ARTICLE	IF	CITATIONS
37	Synthesis of highly functionalized barbituric acids and study of their interactions with p-glycoprotein and Mg <sup>2+</sup> – Potential candidates for multi drug resistance modulation. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 1256-1262.	5.5	18
38	Design, synthesis and evaluations of acridone derivatives using <i>Candida albicans</i> – Search for MDR modulators led to the identification of an anti-candidiasis agent. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3973-3979.	3.0	30
39	Search for MDR modulators: Design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg <sup>2+</sup> . <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2423-2427.	3.0	35